Receptor & Hormone impact and recovery for common recreational drugs

[placebonaut]

I would like to understand more about receptor impact and repair time, specifically which drugs interact with which receptors and how, drug class groupings, cross tolerance/interaction info, receptor recovery time once the drug has stopped being used.

I've had a look on the forum and this info does exist but spread across multiple threads requiring a bit of digging to find the info. Also had a quick look and AI suggests there's no single paper covering things which means I need to read through and capture info from multiple papers.

My goal is to create a simple table grouped by receptor to show what drug affects which receptor and how long it takes to repair the receptor once all drugs impacting that receptor have stopped being taken.

Before I burn loads of energy on this if anyone has any suggestions for what to read or has something that already provides the info I'd be really grateful if you could share please.

I'll try and collate things in this thread as I figure things out.

My starter for 10 from ChatGPT is to read the following long list of papers - I've checked the 1st few and the do exist, but no ideal if these are the best & most up to date papers to look at, more work needed to even figure out my approach

There is no single paper that comprehensively summarizes all receptor changes and recovery timelines for every major recreational drug (alcohol, cannabis, nicotine, opioids, cocaine, methamphetamine, MDMA, etc.). Different drugs act on different receptor systems, and the evidence comes from different fields (PET imaging, molecular neuroscience, clinical addiction research).


However, there is a strong scientific consensus on several broad principles:

• Repeated drug exposure produces neuroadaptations (changes in receptors, transporters, synaptic strength, and neural circuits).
• Different drug classes affect different neurotransmitter systems (dopamine, glutamate, GABA, opioid, cannabinoid, serotonin, acetylcholine).
• Many of these changes are partially or substantially reversible with prolonged abstinence, although recovery can take weeks to years depending on the drug and extent of use.
• Some changes may persist after heavy, long-term exposure, but persistent imaging changes do not necessarily mean permanent impairment in function.

If you only read one paper, I would recommend this one:

1. Neurobiology of addiction: a neurocircuitry analysis (2016)​

Authors: George F. Koob & Nora D. Volkow (two of the world's leading addiction neuroscientists)


Published in The Lancet Psychiatry


Free full text:


Neurobiology of addiction: a neurocircuitry analysis (PMC)


Why it's recommended:

• Written as a consensus review by leaders in the field.
• Summarizes how all major classes of addictive drugs alter brain circuitry.
• Covers dopamine, opioid peptides, GABA, glutamate, serotonin, stress systems, and executive control.
• Discusses both neuroadaptation and recovery during abstinence.

---

The best review papers covering the scientific consensus​

2. The Neurobiology of Addiction: An Overview​

Free:


The Neurobiology of Addiction: An Overview (PMC)


A broad overview explaining:

• reward pathways
• receptor adaptation
• tolerance
• dependence
• withdrawal
• recovery mechanisms

This is an excellent introduction.

---

3. The neurobiology of addiction​

Free:


The neurobiology of addiction (PMC)


Good clinical review covering:

• dopamine
• receptor changes
• why addiction develops
• imaging evidence
• implications for recovery

---

4. Addiction and the brain: The neurobiology of compulsion and its persistence​

Nature Reviews Neuroscience


Nature Reviews article


A landmark review explaining:

• why addiction causes lasting brain changes
• synaptic plasticity
• molecular mechanisms
• persistence after drug cessation

Although published in 2001, it remains highly influential.

---

5. Synaptic plasticity and addiction​

Nature Reviews Neuroscience


Synaptic plasticity and addiction


Focuses on:

• receptor regulation
• glutamate
• dopamine
• long-term potentiation (LTP)
• long-term depression (LTD)
• why recovery takes time

---

Key papers on recovery of specific receptor systems​

These are the studies most often cited when discussing recovery after abstinence:

Cannabis (CB1 receptors)​

Rapid reversibility of cannabinoid CB1 receptor downregulation in cannabis users


Hirvonen et al., Molecular Psychiatry (2012)


This PET imaging study found widespread reductions in CB1 receptor availability in chronic cannabis users that largely normalized after about four weeks of monitored abstinence.


PubMed:


Hirvonen et al. (2012) PubMed record

---

Nicotine (nicotinic acetylcholine receptors)​

Brody et al.


PET studies consistently show α4β2 nicotinic receptor upregulation in smokers that gradually returns toward normal over weeks to months after cessation.

---

Cocaine (dopamine D2 receptors)​

Volkow et al.


PET imaging studies demonstrated reduced striatal dopamine D2 receptor availability in cocaine dependence, with partial recovery during prolonged abstinence.


Representative PubMed page:


Volkow et al. on dopamine D2 receptors and cocaine dependence

---

Methamphetamine (dopamine transporters)​

Volkow and colleagues, along with Chang and colleagues, reported PET evidence of reduced dopamine transporter availability in chronic methamphetamine users, with substantial—but often incomplete—recovery after extended abstinence.


Representative PubMed page:


Volkow et al. on dopamine transporter recovery after methamphetamine abstinence

---

Overall scientific consensus​

Across reviews from The Lancet Psychiatry, Nature Reviews Neuroscience, and NIH-affiliated authors, there is broad agreement that:

• Repeated use of addictive drugs induces neuroplastic changes in receptors, transporters, and neural circuits.
• The specific neurotransmitter systems affected differ by drug class (for example, CB1 for cannabis, nicotinic receptors for nicotine, μ-opioid receptors for opioids, dopamine and glutamate systems across many substances).
• Recovery begins after abstinence and often continues over weeks, months, or years.
• Functional recovery is common, but the rate and completeness vary with the substance, duration and intensity of use, and individual factors.
• Lasting neurobiological changes can remain in some people with prolonged heavy use, but these do not necessarily imply irreversible cognitive or behavioral deficits.

These reviews and studies represent the mainstream view reflected in leading neuroscience journals and are widely cited within the addiction research community.

 

[Allylbenzene]

My goal is to create a simple table grouped by receptor to show what drug affects which receptor and how long it takes to repair the receptor once all drugs impacting that receptor have stopped being taken.

You'll also have to account for (and consider) the hormonal system and it's myriad pharmacological downstream effects and influences. These affect receptors directly and indirectly.

 

[placebonaut]

You'll also have to account for (and consider) the hormonal system and it's myriad pharmacological downstream effects and influences. These affect receptors directly and indirectly.

I'm learning every day, didn't even know about this, but it makes sense.

another thing to add to my to read list, thanks for flagging it

 

[placebonaut]

AI view on receptor and hormone recovery - had to split over 2 posts as it's too much for 1 post.

Spoiler: Single Drug Use Recovery

Primary receptor / target

Drug

Exposure assumption

Drug elimination range

Elimination average days

Receptor adaptation recovery after elimination range

Receptor recovery average days after elimination

Total receptor recovery from last dose range

Total receptor recovery average days

Hormone/endocrine effects

Hormone recovery after elimination range

Hormone recovery average days

Total hormone recovery from last dose range

Total hormone recovery average days

Evidence confidence

Evidence type

Notes / supporting papers

Recovery index score (0-100)

Receptor adaptation severity score (0-100)

Neuroadaptation type

Confidence weighted recovery estimate (days)

GABA-A

Ethanol

Single intoxication dose

12-24 hours

0.75​

Minimal adaptation to 1 week

3​

1-7 days

3.75​

Reduced vasopressin; transient cortisol increase

1-3 days

2​

2-4 days

2.5​

High

Human pharmacology and endocrine studies

Acute alcohol effects resolve faster than chronic GABA-A adaptations

10​

15​

Receptor modulation

4​

GABA-A

Diazepam

Single dose

2-5 days

3.5​

Minimal adaptation to several days

2​

3-7 days

5.5​

Minimal direct hormonal effect

1-3 days

2​

3-7 days

5.5​

Medium

Human benzodiazepine pharmacokinetic studies

Long half-life contributes to total recovery time

15​

20​

Receptor modulation

4​

GABA-A

Alprazolam

Single dose

1-3 days

2​

Minimal adaptation to several days

2​

2-5 days

4​

Minimal direct hormonal effect

1-3 days

2​

2-5 days

4​

Medium

Human benzodiazepine studies

Short acting benzodiazepine with rapid clearance

15​

25​

Receptor modulation

3​

GABA-A

Clonazepam

Single dose

3-6 days

4.5​

Minimal adaptation to several days

2​

5-10 days

6.5​

Minimal direct hormonal effect

1-3 days

2​

5-10 days

6.5​

Medium

Human pharmacokinetic studies

Long half-life delays clearance

15​

20​

Receptor modulation

5​

GABA-A

Carisoprodol

Single dose

1-3 days

2​

Minimal adaptation to several days

2​

3-7 days

4​

Minimal endocrine effects

1-3 days

2​

3-7 days

4​

Low-Medium

Pharmacology studies

Effects largely through meprobamate metabolite

15​

25​

Receptor modulation

3​

GABA-A

Meprobamate

Single dose

2-4 days

3​

Minimal adaptation to several days

2​

4-10 days

6​

Minimal endocrine effects

1-3 days

2​

4-10 days

6​

Medium

Sedative studies

Older GABAergic sedative

15​

25​

Receptor modulation

6​

GABA-B

GHB

Single dose

6-24 hours

0.6​

Minimal adaptation to several days

2​

1-5 days

2.5​

Transient growth hormone increase; possible prolactin effects

1-3 days

2​

1-5 days

2.5​

Medium

Human endocrine studies

Rapid tolerance possible with repeated use

10​

20​

Receptor modulation

2​

GABA-B

GBL

Single dose

2-8 hours

0.2​

Minimal adaptation to several days

2​

1-5 days

2.2​

Similar to GHB

1-3 days

2​

1-5 days

2.2​

Medium

Pharmacokinetic studies

Converted rapidly to GHB

10​

20​

Receptor modulation

2​

Alpha-2-delta calcium channel

Pregabalin

Single dose

1-3 days

2​

Minimal adaptation

2​

2-5 days

4​

Minimal endocrine effects

No significant change expected

0​

2-5 days

4​

Medium

Clinical pharmacology studies

Acts through calcium channels rather than GABA receptors

10​

15​

Excitatory signalling reduction

4​

Alpha-2-delta calcium channel

Gabapentin

Single dose

1-2 days

1.5​

Minimal adaptation

2​

2-5 days

3.5​

Minimal endocrine effects

No significant change expected

0​

2-5 days

3.5​

Medium

Clinical pharmacology studies

Reduces excitatory neurotransmitter release

10​

15​

Excitatory signalling reduction

4​

Mu opioid receptor

Heroin

Single exposure

1-3 days

2​

Several days

3​

3-7 days

5​

Transient reproductive hormone suppression possible

1-2 weeks

7​

1-3 weeks

9​

Medium

Human opioid endocrine studies

Single exposure usually produces short receptor adaptation

20​

35​

Receptor desensitization

7​

Mu opioid receptor

Morphine

Single exposure

1-3 days

2​

Several days

3​

3-7 days

5​

Transient prolactin increase and endocrine effects

1-2 weeks

7​

1-3 weeks

9​

Medium

Human opioid studies

Acute MOR activation affects pituitary hormones

20​

35​

Receptor desensitization

7​

Mu opioid receptor

Fentanyl

Single exposure

1-3 days

2​

Several days

3​

3-7 days

5​

Transient reproductive axis suppression

1-2 weeks

7​

1-3 weeks

9​

Medium

Clinical opioid studies

High potency opioid receptor activation

25​

40​

Receptor desensitization

7​

CB1 cannabinoid receptor

THC

Single exposure

Days-weeks

3.5​

Days to 2 weeks

5​

1-3 weeks

8.5​

Transient cortisol and appetite hormone changes

1-7 days

4​

1-3 weeks

8.5​

High

Human CB1 PET studies

Single exposure causes limited CB1 downregulation

20​

25​

Receptor internalization

9​

CB1 cannabinoid receptor

Synthetic cannabinoids

Single exposure

Hours-days

1​

Days to weeks

7​

1-3 weeks

8​

Possible cortisol changes

Days-weeks

7​

1-3 weeks

8​

Low-Medium

Mechanistic studies

Full CB1 agonism may produce stronger signalling effects

25​

40​

Receptor internalization

12​

Dopamine transporter (DAT)

Cocaine

Single recreational dose

Hours-2 days

0.75​

Minimal adaptation to several days

3​

3-5 days

3.75​

Increased cortisol; increased adrenaline; sympathetic activation

1-3 days

2​

2-5 days

2.75​

High

Human pharmacology studies

DAT blockade resolves rapidly after elimination

20​

25​

Transporter modulation

4​

Dopamine transporter and norepinephrine transporter

Amphetamine

Single recreational dose

1-3 days

2​

Several days

3​

3-7 days

5​

Increased cortisol and catecholamines

1-3 days

2​

3-7 days

5​

High

Human stimulant studies

Single exposure produces temporary monoamine changes

25​

30​

Transporter modulation

5​

Dopamine transporter (DAT)

Methamphetamine

Single recreational dose

2-5 days

3.5​

Days-weeks

10​

2-4 weeks

13.5​

Increased cortisol; catecholamine activation

Days-weeks

10​

2-4 weeks

13.5​

Medium-High

PET and SPECT studies

High doses can produce longer dopamine disruption than amphetamine

35​

45​

Transporter modulation and circuit adaptation

15​

Serotonin transporter (SERT)

MDMA

Single recreational dose

1-3 days

2​

Several days to weeks

14​

2-4 weeks

16​

Increased oxytocin; increased prolactin; increased cortisol

1-3 weeks

14​

2-4 weeks

16​

High

Human PET transporter studies

Temporary SERT changes documented after exposure

40​

45​

Transporter modulation and neurotransmitter depletion

16​

DAT SERT NET

Mephedrone

Single recreational dose

1-3 days

2​

Days-weeks

10​

2-3 weeks

12​

Increased cortisol; catecholamine activation

1-2 weeks

10​

2-3 weeks

12​

Medium

Human and animal monoamine studies

Mechanism overlaps stimulant and empathogen effects

35​

40​

Transporter modulation

12​

5-HT2A serotonin receptor

LSD

Single psychedelic exposure

1-3 days

1.5​

Days to 2 weeks

5​

5-14 days

6.5​

Transient cortisol increase

Days

2​

3-14 days

4​

High

Human psychedelic tolerance studies

Rapid receptor tolerance develops

20​

30​

Receptor desensitization

7​

5-HT2A serotonin receptor

Psilocybin

Single psychedelic exposure

Less than 1 day

0.5​

Days to 2 weeks

5​

3-14 days

5.5​

Transient cortisol increase; possible growth hormone effects

Days

2​

2-14 days

2.5​

High

Human psychedelic studies

Short lived 5-HT2A adaptation

20​

30​

Receptor desensitization

6​

5-HT2A serotonin receptor

2C-B

Single psychedelic exposure

1-2 days

1​

Days to 2 weeks

5​

3-14 days

6​

Possible cortisol changes

Days

2​

3-14 days

3​

Medium

Phenethylamine pharmacology studies

Recovery estimates based on related serotonergic psychedelics

25​

35​

Receptor desensitization

6​

NMDA glutamate receptor

Ketamine

Single recreational dose

1-3 days

2​

Days-weeks

7​

1-3 weeks

9​

Increased cortisol; increased catecholamines

1-7 days

4​

1-3 weeks

6​

High

Human ketamine studies

Downstream glutamate adaptation resolves faster after isolated exposure

30​

35​

Glutamate signalling adaptation

9​

NMDA glutamate receptor

Dextromethorphan

Single recreational dose

1-3 days

2​

Days-weeks

7​

1-3 weeks

9​

Possible serotonin related endocrine effects

1-2 weeks

7​

1-3 weeks

9​

Medium

Pharmacology studies

Multiple mechanisms including NMDA, sigma-1, and serotonin effects

30​

35​

Glutamate signalling adaptation

11​

NMDA glutamate receptor

Nitrous oxide

Single exposure

Minutes-hours

0.1​

Hours-days

1​

1-3 days

1.1​

Transient stress response

Less than 1 week

2​

1-3 days

1.5​

Medium

Clinical anesthesia studies

Short exposure produces limited receptor adaptation

5​

10​

Glutamate receptor modulation

1​

Nicotinic acetylcholine receptor

Nicotine

Single exposure

Hours-3 days

1​

Several days

3​

3-7 days

4​

Increased adrenaline; increased cortisol; insulin effects

1-3 days

2​

3-7 days

3​

High

Human nicotinic receptor studies

Acute activation differs from chronic receptor upregulation

15​

25​

Receptor activation

4​

Kappa opioid receptor

Salvinorin A

Single exposure

Hours

0.25​

Hours-days

1​

1-3 days

1.25​

Limited endocrine data

Unknown

0​

1-3 days

1.25​

Low-Medium

Receptor binding studies

Very short acting KOR agonist

5​

15​

Receptor activation

1​

Spoiler: Recreational (weekly to monthly use) Recovery

Primary receptor / target

Drug

Exposure assumption

Drug elimination range

Elimination average days

Receptor adaptation recovery after elimination range

Receptor recovery average days after elimination

Total receptor recovery from last dose range

Total receptor recovery average days

Hormone/endocrine effects

Hormone recovery after elimination range

Hormone recovery average days

Total hormone recovery from last dose range

Total hormone recovery average days

Evidence confidence

Evidence type

Notes / supporting papers

Recovery index score (0-100)

Receptor adaptation severity score (0-100)

Neuroadaptation type

Confidence weighted recovery estimate (days)

GABA-A

Ethanol

Weekly recreational use

12-24 hours

0.75​

1-4 weeks

17.5​

1-4 weeks

18​

Reduced GABA-A sensitivity; increased glutamate activity; altered cortisol regulation

Weeks

21​

Weeks-months

60​

High

Human withdrawal and receptor studies

Chronic alcohol studies demonstrate GABA-A adaptation and NMDA upregulation

45​

55​

Receptor downregulation and excitatory rebound

18​

GABA-A

Diazepam

Weekly use

3-10 days

6.5​

2-6 weeks

28​

3-8 weeks

42​

Possible HPA axis changes

Weeks

21​

Weeks

42​

Medium

Human benzodiazepine tolerance studies

Repeated exposure causes GABA-A adaptation and tolerance

40​

50​

Receptor desensitization

32​

GABA-A

Alprazolam

Weekly use

1-3 days

2​

2-6 weeks

28​

2-8 weeks

35​

Possible cortisol regulation changes

Weeks

21​

Weeks

35​

Medium

Human benzodiazepine studies

Short acting benzodiazepines can produce strong tolerance

45​

60​

Receptor desensitization

26​

GABA-A

Clonazepam

Weekly use

3-6 days

4.5​

2-8 weeks

35​

3-10 weeks

50​

Minimal direct endocrine effects; possible stress axis changes

Weeks

21​

Weeks

50​

Medium

Human benzodiazepine studies

Long duration may delay subjective recovery

40​

50​

Receptor desensitization

38​

GABA-A

Carisoprodol

Weekly use

1-3 days plus metabolite

2​

1-4 weeks

17.5​

2-5 weeks

24​

Minimal endocrine effects

Minimal

7​

2-5 weeks

24​

Low-Medium

Pharmacology studies

Adaptation mainly through meprobamate metabolite

35​

45​

Receptor modulation

24​

GABA-A

Meprobamate

Weekly use

2-5 days

3.5​

2-6 weeks

28​

3-8 weeks

42​

Minimal endocrine effects

Minimal

7​

3-8 weeks

42​

Medium

Sedative-hypnotic studies

Older sedative with tolerance development

40​

50​

Receptor desensitization

32​

GABA-B

GHB

Weekly use

6-24 hours

0.6​

1-3 weeks

14​

1-4 weeks

17​

Altered growth hormone and prolactin signalling

1-3 weeks

14​

1-4 weeks

17​

Medium

Human endocrine studies

Rapid tolerance develops with repeated use

35​

50​

Receptor desensitization

13​

GABA-B

GBL

Weekly use

2-8 hours

0.2​

1-3 weeks

14​

1-4 weeks

14​

Similar to GHB

1-3 weeks

14​

1-4 weeks

14​

Medium

Clinical pharmacology studies

Conversion to GHB produces similar adaptation

35​

50​

Receptor desensitization

11​

Alpha-2-delta calcium channel

Pregabalin

Weekly use

1-3 days

2​

1-3 weeks

14​

1-4 weeks

16​

Minimal direct endocrine effects

Minimal

0​

1-4 weeks

16​

Medium

Clinical studies

Calcium channel adaptation rather than GABA receptor adaptation

25​

30​

Excitatory signalling reduction

16​

Alpha-2-delta calcium channel

Gabapentin

Weekly use

1-2 days

1.5​

1-3 weeks

14​

1-4 weeks

15.5​

Minimal endocrine effects

Minimal

0​

1-4 weeks

15.5​

Medium

Clinical studies

Lower adaptation than sedative drugs

25​

30​

Excitatory signalling reduction

16​

Mu opioid receptor

Heroin

Weekly use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

38​

Reduced GnRH; reduced LH and testosterone signalling

Weeks-months

60​

1-3 months

90​

Medium

Human opioid endocrine studies

Repeated opioid exposure causes MOR desensitization and hormonal suppression

65​

75​

Receptor desensitization and endocrine adaptation

38​

Mu opioid receptor

Morphine

Weekly use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

38​

Reduced LH and testosterone possible

Weeks-months

60​

1-3 months

90​

Medium

Opioid endocrine studies

MOR adaptation persists beyond drug clearance

65​

75​

Receptor desensitization and endocrine adaptation

38​

Mu opioid receptor

Fentanyl

Weekly use

1-3 days

2​

3-8 weeks

42​

4-10 weeks

52​

Opioid induced hypogonadism risk

Months

90​

2-4 months

120​

Medium

Clinical opioid studies

High potency may accelerate tolerance

75​

85​

Receptor desensitization and endocrine adaptation

52​

CB1 cannabinoid receptor

THC

Weekly use

Days-weeks

14​

2-6 weeks

28​

3-8 weeks

45​

Possible reduced GnRH and sex hormone signalling

Weeks-months

60​

1-3 months

75​

High

Human PET imaging

Hirvonen et al. demonstrated CB1 receptor downregulation and recovery after abstinence

60​

70​

Receptor internalization and signalling adaptation

45​

CB1 cannabinoid receptor

Synthetic cannabinoids

Weekly use

Hours-days

1​

2-8 weeks

35​

3-10 weeks

45​

Possible cortisol changes

Weeks

30​

Weeks-months

60​

Low-Medium

Mechanistic studies

Full CB1 agonism may produce stronger adaptation than THC

70​

80​

Receptor internalization and signalling adaptation

34​

Dopamine transporter (DAT)

Cocaine

Weekly recreational use

Hours-2 days

0.75​

2-8 weeks

35​

2-10 weeks

36​

Repeated cortisol elevation; increased sympathetic activity

Weeks

30​

1-3 months

60​

High

Human PET studies and clinical studies

DAT availability and dopamine signalling adapt with repeated exposure

60​

70​

Transporter regulation and reward circuit adaptation

36​

Dopamine transporter and norepinephrine transporter

Amphetamine

Weekly recreational use

1-3 days

2​

2-8 weeks

35​

3-10 weeks

50​

Increased cortisol and catecholamines

Weeks-months

60​

2-3 months

90​

Medium-High

Human stimulant studies

Repeated exposure alters dopamine release and transporter regulation

65​

70​

Transporter regulation and neurotransmitter adaptation

50​

Dopamine transporter (DAT)

Methamphetamine

Weekly recreational use

2-5 days

3.5​

1-3 months

60​

2-4 months

90​

Cortisol dysregulation; stress axis activation; possible reproductive effects

Months

90​

3-6 months

150​

High

Human PET and SPECT imaging

Dopamine transporter recovery occurs over months in many users

80​

90​

Transporter loss, neurotransmitter depletion, circuit adaptation

90​

Serotonin transporter (SERT)

MDMA

Weekly recreational use

1-3 days

2​

1-3 months

60​

2-4 months

90​

Increased prolactin; increased oxytocin; cortisol changes; possible ADH disruption

1-3 months

60​

2-6 months

120​

High

Human PET transporter imaging studies

Reduced serotonin transporter availability observed in frequent users

80​

85​

Transporter regulation and serotonin depletion

90​

DAT SERT NET

Mephedrone

Weekly recreational use

1-3 days

2​

2-8 weeks

35​

3-10 weeks

50​

Cortisol elevation; catecholamine activation; possible prolactin changes

Weeks-months

60​

2-3 months

90​

Medium

Human and animal monoamine studies

Overlaps mechanistically with cocaine and MDMA

65​

75​

Transporter regulation

50​

5-HT2A serotonin receptor

LSD

Weekly recreational use

1-3 days

1.5​

1-3 weeks

14​

2-4 weeks

16​

Transient cortisol elevation

1-3 weeks

14​

2-4 weeks

16​

High

Human psychedelic tolerance studies

Rapid 5-HT2A downregulation and recovery

35​

45​

Receptor desensitization

16​

5-HT2A serotonin receptor

Psilocybin

Weekly recreational use

Less than 1 day

0.5​

1-3 weeks

14​

1-3 weeks

14​

Transient cortisol elevation; possible growth hormone effects

1-3 weeks

14​

1-3 weeks

14​

High

Human psychedelic studies

Tolerance prevents continuous effect with frequent use

35​

45​

Receptor desensitization

14​

5-HT2A serotonin receptor

2C-B

Weekly recreational use

1-2 days

1​

1-3 weeks

14​

2-4 weeks

15​

Possible cortisol changes

1-3 weeks

14​

2-4 weeks

15​

Medium

Phenethylamine pharmacology studies

Recovery estimated from related serotonergic psychedelics

40​

50​

Receptor desensitization

15​

NMDA glutamate receptor

Ketamine

Weekly recreational use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

42​

Increased cortisol and catecholamines

Weeks

21​

1-2 months

45​

High

Human ketamine studies

Repeated exposure alters glutamate plasticity pathways

55​

60​

Glutamate signalling adaptation

42​

NMDA glutamate receptor

Dextromethorphan

Weekly recreational use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

42​

Possible serotonergic endocrine effects

Weeks

21​

1-2 months

45​

Medium

Pharmacology studies

Multiple targets complicate recovery estimates

50​

55​

Glutamate and serotonin adaptation

42​

NMDA glutamate receptor

Nitrous oxide

Weekly recreational use

Hours-days

0.5​

Days-weeks

7​

1-3 weeks

8​

Stress response activation; possible B12-related effects

Weeks

21​

1-2 months

30​

Medium

Toxicology studies

Repeated use creates risks beyond receptor adaptation

40​

45​

Glutamate modulation and metabolic adaptation

8​

Nicotinic acetylcholine receptor

Nicotine

Weekly recreational use

1-3 days

1​

2-8 weeks

35​

3-10 weeks

45​

Increased adrenaline; cortisol changes; insulin effects

Weeks-months

60​

2-3 months

90​

High

Human PET receptor studies

Repeated nicotine causes receptor upregulation

70​

80​

Receptor upregulation and signalling adaptation

45​

Kappa opioid receptor

Salvinorin A

Weekly recreational use

Hours

0.25​

Days-weeks

7​

1-3 weeks

7​

Minimal endocrine data

Unknown

0​

1-3 weeks

7​

Low-Medium

Receptor binding studies

Limited evidence for long-term adaptation

20​

30​

Receptor adaptation

7​

 

[placebonaut]

Spoiler: Heavy/chronic use Recovery

Primary receptor / target

Drug

Exposure assumption

Drug elimination range

Elimination average days

Receptor adaptation recovery after elimination range

Receptor recovery average days after elimination

Total receptor recovery from last dose range

Total receptor recovery average days

Hormone/endocrine effects

Hormone recovery after elimination range

Hormone recovery average days

Total hormone recovery from last dose range

Total hormone recovery average days

Evidence confidence

Evidence type

Notes / supporting papers

Recovery index score (0-100)

Receptor adaptation severity score (0-100)

Neuroadaptation type

Confidence weighted recovery estimate (days)

GABA-A

Ethanol

Weekly recreational use

12-24 hours

0.75​

1-4 weeks

17.5​

1-4 weeks

18​

Reduced GABA-A sensitivity; increased glutamate activity; altered cortisol regulation

Weeks

21​

Weeks-months

60​

High

Human withdrawal and receptor studies

Chronic alcohol studies demonstrate GABA-A adaptation and NMDA upregulation

45​

55​

Receptor downregulation and excitatory rebound

18​

GABA-A

Diazepam

Weekly use

3-10 days

6.5​

2-6 weeks

28​

3-8 weeks

42​

Possible HPA axis changes

Weeks

21​

Weeks

42​

Medium

Human benzodiazepine tolerance studies

Repeated exposure causes GABA-A adaptation and tolerance

40​

50​

Receptor desensitization

32​

GABA-A

Alprazolam

Weekly use

1-3 days

2​

2-6 weeks

28​

2-8 weeks

35​

Possible cortisol regulation changes

Weeks

21​

Weeks

35​

Medium

Human benzodiazepine studies

Short acting benzodiazepines can produce strong tolerance

45​

60​

Receptor desensitization

26​

GABA-A

Clonazepam

Weekly use

3-6 days

4.5​

2-8 weeks

35​

3-10 weeks

50​

Minimal direct endocrine effects; possible stress axis changes

Weeks

21​

Weeks

50​

Medium

Human benzodiazepine studies

Long duration may delay subjective recovery

40​

50​

Receptor desensitization

38​

GABA-A

Carisoprodol

Weekly use

1-3 days plus metabolite

2​

1-4 weeks

17.5​

2-5 weeks

24​

Minimal endocrine effects

Minimal

7​

2-5 weeks

24​

Low-Medium

Pharmacology studies

Adaptation mainly through meprobamate metabolite

35​

45​

Receptor modulation

24​

GABA-A

Meprobamate

Weekly use

2-5 days

3.5​

2-6 weeks

28​

3-8 weeks

42​

Minimal endocrine effects

Minimal

7​

3-8 weeks

42​

Medium

Sedative-hypnotic studies

Older sedative with tolerance development

40​

50​

Receptor desensitization

32​

GABA-B

GHB

Weekly use

6-24 hours

0.6​

1-3 weeks

14​

1-4 weeks

17​

Altered growth hormone and prolactin signalling

1-3 weeks

14​

1-4 weeks

17​

Medium

Human endocrine studies

Rapid tolerance develops with repeated use

35​

50​

Receptor desensitization

13​

GABA-B

GBL

Weekly use

2-8 hours

0.2​

1-3 weeks

14​

1-4 weeks

14​

Similar to GHB

1-3 weeks

14​

1-4 weeks

14​

Medium

Clinical pharmacology studies

Conversion to GHB produces similar adaptation

35​

50​

Receptor desensitization

11​

Alpha-2-delta calcium channel

Pregabalin

Weekly use

1-3 days

2​

1-3 weeks

14​

1-4 weeks

16​

Minimal direct endocrine effects

Minimal

0​

1-4 weeks

16​

Medium

Clinical studies

Calcium channel adaptation rather than GABA receptor adaptation

25​

30​

Excitatory signalling reduction

16​

Alpha-2-delta calcium channel

Gabapentin

Weekly use

1-2 days

1.5​

1-3 weeks

14​

1-4 weeks

15.5​

Minimal endocrine effects

Minimal

0​

1-4 weeks

15.5​

Medium

Clinical studies

Lower adaptation than sedative drugs

25​

30​

Excitatory signalling reduction

16​

Mu opioid receptor

Heroin

Weekly use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

38​

Reduced GnRH; reduced LH and testosterone signalling

Weeks-months

60​

1-3 months

90​

Medium

Human opioid endocrine studies

Repeated opioid exposure causes MOR desensitization and hormonal suppression

65​

75​

Receptor desensitization and endocrine adaptation

38​

Mu opioid receptor

Morphine

Weekly use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

38​

Reduced LH and testosterone possible

Weeks-months

60​

1-3 months

90​

Medium

Opioid endocrine studies

MOR adaptation persists beyond drug clearance

65​

75​

Receptor desensitization and endocrine adaptation

38​

Mu opioid receptor

Fentanyl

Weekly use

1-3 days

2​

3-8 weeks

42​

4-10 weeks

52​

Opioid induced hypogonadism risk

Months

90​

2-4 months

120​

Medium

Clinical opioid studies

High potency may accelerate tolerance

75​

85​

Receptor desensitization and endocrine adaptation

52​

CB1 cannabinoid receptor

THC

Weekly use

Days-weeks

14​

2-6 weeks

28​

3-8 weeks

45​

Possible reduced GnRH and sex hormone signalling

Weeks-months

60​

1-3 months

75​

High

Human PET imaging

Hirvonen et al. demonstrated CB1 receptor downregulation and recovery after abstinence

60​

70​

Receptor internalization and signalling adaptation

45​

CB1 cannabinoid receptor

Synthetic cannabinoids

Weekly use

Hours-days

1​

2-8 weeks

35​

3-10 weeks

45​

Possible cortisol changes

Weeks

30​

Weeks-months

60​

Low-Medium

Mechanistic studies

Full CB1 agonism may produce stronger adaptation than THC

70​

80​

Receptor internalization and signalling adaptation

34​

Dopamine transporter (DAT)

Cocaine

Weekly recreational use

Hours-2 days

0.75​

2-8 weeks

35​

2-10 weeks

36​

Repeated cortisol elevation; increased sympathetic activity

Weeks

30​

1-3 months

60​

High

Human PET studies and clinical studies

DAT availability and dopamine signalling adapt with repeated exposure

60​

70​

Transporter regulation and reward circuit adaptation

36​

Dopamine transporter and norepinephrine transporter

Amphetamine

Weekly recreational use

1-3 days

2​

2-8 weeks

35​

3-10 weeks

50​

Increased cortisol and catecholamines

Weeks-months

60​

2-3 months

90​

Medium-High

Human stimulant studies

Repeated exposure alters dopamine release and transporter regulation

65​

70​

Transporter regulation and neurotransmitter adaptation

50​

Dopamine transporter (DAT)

Methamphetamine

Weekly recreational use

2-5 days

3.5​

1-3 months

60​

2-4 months

90​

Cortisol dysregulation; stress axis activation; possible reproductive effects

Months

90​

3-6 months

150​

High

Human PET and SPECT imaging

Dopamine transporter recovery occurs over months in many users

80​

90​

Transporter loss, neurotransmitter depletion, circuit adaptation

90​

Serotonin transporter (SERT)

MDMA

Weekly recreational use

1-3 days

2​

1-3 months

60​

2-4 months

90​

Increased prolactin; increased oxytocin; cortisol changes; possible ADH disruption

1-3 months

60​

2-6 months

120​

High

Human PET transporter imaging studies

Reduced serotonin transporter availability observed in frequent users

80​

85​

Transporter regulation and serotonin depletion

90​

DAT SERT NET

Mephedrone

Weekly recreational use

1-3 days

2​

2-8 weeks

35​

3-10 weeks

50​

Cortisol elevation; catecholamine activation; possible prolactin changes

Weeks-months

60​

2-3 months

90​

Medium

Human and animal monoamine studies

Overlaps mechanistically with cocaine and MDMA

65​

75​

Transporter regulation

50​

5-HT2A serotonin receptor

LSD

Weekly recreational use

1-3 days

1.5​

1-3 weeks

14​

2-4 weeks

16​

Transient cortisol elevation

1-3 weeks

14​

2-4 weeks

16​

High

Human psychedelic tolerance studies

Rapid 5-HT2A downregulation and recovery

35​

45​

Receptor desensitization

16​

5-HT2A serotonin receptor

Psilocybin

Weekly recreational use

Less than 1 day

0.5​

1-3 weeks

14​

1-3 weeks

14​

Transient cortisol elevation; possible growth hormone effects

1-3 weeks

14​

1-3 weeks

14​

High

Human psychedelic studies

Tolerance prevents continuous effect with frequent use

35​

45​

Receptor desensitization

14​

5-HT2A serotonin receptor

2C-B

Weekly recreational use

1-2 days

1​

1-3 weeks

14​

2-4 weeks

15​

Possible cortisol changes

1-3 weeks

14​

2-4 weeks

15​

Medium

Phenethylamine pharmacology studies

Recovery estimated from related serotonergic psychedelics

40​

50​

Receptor desensitization

15​

NMDA glutamate receptor

Ketamine

Weekly recreational use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

42​

Increased cortisol and catecholamines

Weeks

21​

1-2 months

45​

High

Human ketamine studies

Repeated exposure alters glutamate plasticity pathways

55​

60​

Glutamate signalling adaptation

42​

NMDA glutamate receptor

Dextromethorphan

Weekly recreational use

1-3 days

2​

2-6 weeks

28​

3-8 weeks

42​

Possible serotonergic endocrine effects

Weeks

21​

1-2 months

45​

Medium

Pharmacology studies

Multiple targets complicate recovery estimates

50​

55​

Glutamate and serotonin adaptation

42​

NMDA glutamate receptor

Nitrous oxide

Weekly recreational use

Hours-days

0.5​

Days-weeks

7​

1-3 weeks

8​

Stress response activation; possible B12-related effects

Weeks

21​

1-2 months

30​

Medium

Toxicology studies

Repeated use creates risks beyond receptor adaptation

40​

45​

Glutamate modulation and metabolic adaptation

8​

Nicotinic acetylcholine receptor

Nicotine

Weekly recreational use

1-3 days

1​

2-8 weeks

35​

3-10 weeks

45​

Increased adrenaline; cortisol changes; insulin effects

Weeks-months

60​

2-3 months

90​

High

Human PET receptor studies

Repeated nicotine causes receptor upregulation

70​

80​

Receptor upregulation and signalling adaptation

45​

Kappa opioid receptor

Salvinorin A

Weekly recreational use

Hours

0.25​

Days-weeks

7​

1-3 weeks

7​

Minimal endocrine data

Unknown

0​

1-3 weeks

7​

Low-Medium

Receptor binding studies

Limited evidence for long-term adaptation

20​

30​

Receptor adaptation

7​

 

[placebonaut]

ChatGPT advice on papers:- A small set of highly regarded papers can collectively cover most of your dataset. For a scientific reference backbone, I would use the following.

System covered	Gold-standard paper	What it contributes
General addiction neuroadaptation framework		Probably the best single overview of chronic drug-induced adaptations across dopamine, stress systems, reward circuitry, and withdrawal. Useful as the conceptual framework for your dataset.
Dopamine transporter recovery (methamphetamine)	Volkow et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. Journal of Neuroscience 2001	One of the strongest human demonstrations that a drug-induced transporter change can partially recover over prolonged abstinence. PET-based DAT measurement. (PubMed)
Dopamine recovery nuance	Volkow et al. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. NeuroImage 2015	Important because DAT recovery does not necessarily equal complete dopamine system normalization. Separates transporter recovery from functional recovery. (PubMed)
Serotonin transporter recovery (MDMA)	Buchert et al. A voxel-based PET investigation of long-term effects of ecstasy consumption on brain serotonin transporters. Journal of Neuroscience 2004	Strong human PET evidence that SERT reductions in MDMA users can recover with abstinence. (PubMed)
Serotonin transporter and 5-HT2A changes (MDMA)	Kish et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls. Neuropsychopharmacology 2005	Covers SERT changes using validated PET ligands and examines relationships with abstinence duration. (Nature)
CB1 cannabinoid receptor recovery		One of the best human PET studies of receptor downregulation and recovery after cannabis cessation.
GABA-A receptor recovery (alcohol dependence)	Abi-Dargham et al. Cortical GABA-A-benzodiazepine receptors in recovery from alcohol dependence. Archives of General Psychiatry 1998	Directly examines GABA-A benzodiazepine receptor availability during recovery from alcohol dependence. (JAMA Network)
Nicotinic acetylcholine receptor recovery	Cosgrove et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment. Archives of General Psychiatry 2014	PET evidence for alpha4beta2 nicotinic receptor availability changes in smokers. (PubMed)

I'll go and validate the numbers by looking at the papers but I will prioritise the drugs that I use

AI prompt - which papers provide a summary for the following drugs:- pregablin, GBL, mephedrone, MDMA, amphetamine, Carisoprodol, Meprobamate, cocaine, 2C-B. Provide a table with the papers name, a link to the paper, and a matrix of which drugs & receptors it covers

Spoiler: Table summary for my DOCs

Paper	Link	Pregabalin	GBL / GHB	Mephedrone	MDMA	Amphetamine	Carisoprodol	Meprobamate	Cocaine	2C-B	Main receptor/transporter coverage
Gajraj. "Pregabalin: its pharmacology and use in pain management" (2007)	Pregabalin: its pharmacology and use in pain management	X	-	-	-	-	-	-	-	-	Alpha-2-delta voltage gated calcium channel subunit; reduced glutamate, noradrenaline, serotonin release
Ben-Menachem. "Pregabalin pharmacology and its relevance to clinical practice" (2004)	Pregabalin pharmacology and its relevance to clinical practice	X	-	-	-	-	-	-	-	-	Alpha-2-delta calcium channels; neuronal excitability
Wong et al. "Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential" (2003)	Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential	-	X	-	-	-	-	-	-	-	GHB receptor, GABA-B receptor, dopamine modulation
Simmler et al. "Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances" (2018)	Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances	-	-	X	X	X	-	-	P	-	DAT, NET, SERT, monoamine release, receptor interactions
Verrico, Miller and Madras. "MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters" (2007)	MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment	-	-	-	X	P	-	-	-	-	SERT, DAT, NET
Sulzer et al. "New insights into the mechanism of action of amphetamines" (2007)	New insights into the mechanism of action of amphetamines	-	-	P	X	X	-	-	P	-	DAT, VMAT2, monoamine release, transporter reversal
Liechti et al. "Pharmacological profile of mephedrone analogs and related new psychoactive substances" (2017)	Pharmacological profile of mephedrone analogs and related new psychoactive substances	-	-	X	P	P	-	-	-	-	DAT, NET, SERT, monoamine receptors
Kuhar. "Molecular pharmacology of cocaine: a dopamine hypothesis and its implications" (1992)	Molecular pharmacology of cocaine: a dopamine hypothesis and its implications	-	-	-	-	-	-	-	X	-	DAT, dopamine reward pathway
Ritz et al. / PET cocaine transporter literature	Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy	-	-	-	-	-	-	-	X	-	DAT occupancy, SERT, NET binding
Rho et al. / Carisoprodol GABA-A studies	Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies	-	-	-	-	-	X	X	-	-	GABA-A receptor positive allosteric modulation
Hogenkamp et al. "Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA-A receptors" (2016)	Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABAA receptors	-	-	-	-	-	X	X	-	-	GABA-A receptor subtypes
Psychedelic 5-HT2A receptor reviews (general psychedelic pharmacology)	5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology	-	-	-	-	-	-	-	-	X	5-HT2A receptor signalling, glutamate/plasticity pathways

Best "core reading set" if you want the smallest number of papers

If the goal is to support your receptor dataset with the fewest citations, I would use:

1. Koob and Volkow 2016
   • General addiction neuroadaptation framework
   • Applies across dopamine, stress, reward systems
2. Simmler & Liechti 2018
   • Covers MDMA, amphetamine-like drugs, mephedrone
   • DAT/NET/SERT framework
3. Sulzer 2007
   • Amphetamine and monoamine transporter mechanisms
4. Wong 2003
   • GHB/GBL receptor pharmacology
5. Rho/Hogenkamp GABA-A papers
   • Carisoprodol/meprobamate
6. Gajraj 2007
   • Pregabalin
7. 5-HT2A psychedelic receptor reviews
   • 2C-B class coverage

This set gives a defensible literature foundation for almost every receptor entry in your dataset.


One important gap remains: 2C-B specifically has far less receptor and recovery literature than LSD/psilocybin, so most 2C-B entries are necessarily extrapolated from substituted phenethylamines and 5-HT2A agonist literature rather than direct human receptor recovery studies.

Pregabalin: its pharmacology and use in pain management - PubMed

Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid. It is an alpha2-delta (alpha2-delta) ligand that has analgesic, anticonvulsant, anxiolytic, and sleep-modulating activities. Pregabalin binds potently to the...

pubmed.ncbi.nlm.nih.gov

Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential - PubMed

When administered in pharmacological doses, its powerful central nervous system depressant effects are readily observed. Although some of the neurophysiological actions of GHB could involve alterations in dopaminergic transmission in the basal ganglia, both its physiological and pharmacological...

pubmed.ncbi.nlm.nih.gov

Checking your browser - reCAPTCHA

Checking your browser - reCAPTCHA

 

[Sixx_Psychonaut]

I saw in the research paper about the methamphetamine rejenerative qualities that it can be neuroprotective and promote growth when used in small doses and is used in the medical sector to treat aquired brain injury recovery.

 

[placebonaut]

I saw in the research paper about the methamphetamine rejenerative qualities that it can be neuroprotective and promote growth when used in small doses and is used in the medical sector to treat aquired brain injury recovery.

yes I saw that as well, maybe someone posted about it recently (?? can't remember).

while there might be upside for certain drugs for this exercise I'm not planning on including any, it will just complicate the model - I'm basing much of what I do here on normal "common" doses as well, think that's the easiest way to keep things as consistent and transferable as possible